Compare Page
Cerebrolysin vs Semax
Quick verdict: Cerebrolysin and Semax are both neuroprotective agents with clinical use in post-Soviet medicine, but they differ fundamentally in composition and mechanism. Cerebrolysin is a complex mixture of low-molecular-weight neuropeptides and free amino acids derived from porcine brain tissue — essentially a multi-component neurotrophic cocktail. Semax is a single defined synthetic heptapeptide derived from ACTH(4–10) that acts primarily through BDNF/NGF upregulation. One is a biological mixture; the other is a precision molecule.
Read the full peptide profiles: Cerebrolysin | Semax.
At a Glance: Cerebrolysin vs Semax
Mechanism of Action
Cerebrolysin’s mechanism reflects its complex composition. As a standardised aqueous preparation of enzymatically treated porcine brain proteins, it contains hundreds of low-molecular-weight neuropeptides and free amino acids, many of which have individual neurotrophic properties. The mixture exhibits BDNF-like and GDNF-like neurotrophic activity, promoting neuronal survival, dendritic branching, and synaptic plasticity. It inhibits calpain-mediated neuronal death, modulates GSK-3β signalling (relevant to tau phosphorylation in Alzheimer’s disease), and protects mitochondrial function during ischaemic stress. The multi-target nature of Cerebrolysin is considered both its strength (redundant neuroprotective pathways) and its analytical weakness (harder to attribute effects to specific components).
Semax acts through a far more defined molecular mechanism. Derived from the ACTH(4–10) fragment with a stabilising Pro-Gly-Pro C-terminal extension, Semax has no steroidogenic activity despite its ACTH lineage. Its primary neuroprotective and nootropic effects are mediated through robust upregulation of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) in the brain. Semax also activates melanocortin-4 receptors (MC4R), modulates serotonergic and dopaminergic neurotransmission, and influences the expression of genes involved in neuronal survival and immune response following brain injury. The result is a cognitive-enhancing and neuroprotective profile that’s molecularly traceable.
The core distinction is pharmaceutical philosophy: Cerebrolysin takes a “biological shotgun” approach — delivering a complex neurotrophic mixture that hits multiple targets simultaneously. Semax takes a “precision molecule” approach — a single defined peptide that activates specific neurotrophic pathways. Both converge on BDNF-related neuroprotection, but arrive there through very different pharmacological traditions. For Semax’s comparison with the anxiolytic nootropic Selank, see Selank vs Semax.
Research Evidence
Cerebrolysin has the larger and more internationally diverse evidence base. It has been studied in large randomised controlled trials for acute ischaemic stroke (the CASTA trial, n=1,070), Alzheimer’s disease (multiple RCTs), traumatic brain injury, and vascular dementia. The CASTA trial, while not showing significant superiority for its primary endpoint, demonstrated safety and trends toward improved outcomes in specific subgroups. A Cochrane systematic review of Cerebrolysin in acute ischaemic stroke found insufficient evidence for routine recommendation but acknowledged its neuroprotective biological rationale. Cerebrolysin is approved and used clinically in over 50 countries (primarily in Europe, Asia, and Latin America) for stroke recovery and dementia, though it lacks FDA approval and is not available in the US or UK.
Semax’s clinical evidence is more geographically concentrated but mechanistically deeper. The key stroke study by Gusev et al. demonstrated that intranasal Semax administered within the first hours of ischaemic stroke improved neurological outcomes and reduced infarct volume, leading to its approval in Russia for this indication. Clinical trials have also investigated Semax for cognitive impairment, optic nerve disease, and peptic ulcer healing. The molecular evidence — showing dose-dependent BDNF and NGF upregulation, gene expression changes in immune and vascular pathways following ischaemia, and neuroprotective effects across multiple injury models — provides a mechanistic coherence that Cerebrolysin’s complex mixture cannot match.
From a research methodology perspective, Cerebrolysin’s evidence benefits from Western-style large RCTs and Cochrane-quality systematic reviews. Semax’s evidence benefits from molecular precision — you know exactly what molecule produced the observed effects. Cerebrolysin’s clinical breadth (stroke, Alzheimer’s, TBI) is wider, while Semax’s primary strength is the ability to attribute neuroprotective outcomes to a single defined peptide. Both face the same challenge of limited Western regulatory acceptance despite substantial clinical use elsewhere.
Key Differences
- Composition: Cerebrolysin is a complex biological mixture of hundreds of peptides and amino acids; Semax is a single defined synthetic heptapeptide — fundamentally different pharmaceutical approaches
- Administration route: Cerebrolysin requires IV or IM injection; Semax is administered intranasally — a significant practical difference for research protocol design
- Mechanistic transparency: Semax’s effects can be attributed to a single molecule with defined receptor targets; Cerebrolysin’s effects emerge from a complex mixture where individual contributions are difficult to isolate
- Global availability: Cerebrolysin is approved in 50+ countries; Semax is approved only in Russia and Ukraine — Cerebrolysin has broader clinical adoption
- Source material: Cerebrolysin is derived from porcine brain tissue (biological product); Semax is fully synthetic — different manufacturing and quality control considerations
- Cognitive focus: Semax scores higher for cognitive/nootropic support (7.0 vs 6.5), reflecting its sharper cognitive-enhancement profile versus Cerebrolysin’s broader neuroprotective emphasis
Frequently Asked Questions
Which is better for neuroprotection after stroke?
Both have clinical stroke evidence, but from different perspectives. Cerebrolysin has been tested in larger RCTs (CASTA trial, n=1,070) and is clinically used for stroke recovery in many countries. Semax has smaller but more mechanistically focused stroke trials showing improved outcomes with intranasal administration. The choice in a research context depends on whether multi-target neuroprotection (Cerebrolysin) or defined-molecule, mechanistically traceable neuroprotection (Semax) is the priority.
Is Cerebrolysin’s complex composition an advantage or disadvantage?
Both. The complexity provides redundant neuroprotective pathways — multiple peptides hitting multiple targets simultaneously, which may provide more robust real-world neuroprotection. However, it makes it impossible to determine which specific components are responsible for observed effects, complicating dose optimisation, mechanism-of-action studies, and regulatory approval in countries requiring molecular-level drug characterisation. Semax’s defined structure avoids this problem entirely.
Why isn’t Cerebrolysin approved in the US or UK?
Cerebrolysin’s regulatory challenge in Western markets relates partly to its biological complexity — it’s difficult to fully characterise a multi-component brain extract to the standards required by the FDA or MHRA. The large stroke RCTs (CASTA) did not show definitive primary endpoint success, making the efficacy case for regulatory approval incomplete by Western standards. Despite this, Cerebrolysin is widely used in clinical neurology across Europe, Asia, and Latin America based on its broader evidence portfolio.
Can Semax be used for cognitive enhancement in healthy individuals?
Semax has been investigated for cognitive enhancement beyond neurological disease. Its BDNF/NGF upregulation mechanism supports synaptic plasticity and memory consolidation regardless of baseline neurological status. Russian clinical experience includes use for cognitive optimisation, and preclinical studies show enhanced learning and memory in normal (non-impaired) animal models. However, controlled clinical trials specifically for cognitive enhancement in healthy populations are limited.
Does Cerebrolysin have the same safety concerns as other animal-derived products?
Cerebrolysin is manufactured through enzymatic hydrolysis of porcine brain tissue under standardised conditions, and the final product contains only low-molecular-weight peptides (<10 kDa) and free amino acids — no intact proteins or cellular material. This processing significantly reduces prion and immunogenicity risks compared to crude tissue extracts. Post-marketing surveillance across decades and millions of doses suggests a favourable safety profile, with injection-site reactions and dizziness being the most common adverse effects.
How does Semax compare to Selank for neuroprotection?
Semax scores higher for neuroprotection (6.5 vs 5.5) and cognitive/nootropic support (7.0 vs 6.5) compared to Selank. Semax’s neuroprotective effects are mediated through BDNF/NGF upregulation and have clinical evidence in stroke recovery. Selank’s neuroprotection is secondary to its anxiolytic mechanism — it protects neurons through GABAergic modulation and enkephalin regulation rather than direct neurotrophic factor upregulation. See Selank vs Semax for the full comparison.
Are Cerebrolysin and Semax approved by WADA?
Neither Cerebrolysin nor Semax is specifically listed on the WADA prohibited list. However, athletes should consult current prohibited lists and their anti-doping authorities, as regulatory classifications can change. Both substances are primarily used in clinical neurology contexts rather than performance enhancement.
References
- Heiss WD, Brainin M, Bornstein NM, et al. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke. 2012;43(3):630-636. PMID: 22282886
- Gusev EI, Skvortsova VI, Miasoedov NF, et al. Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(6):26-34. PMID: 11517472
- Alvarez XA, Cacabelos R, Laredo M, et al. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer’s disease. Eur J Neurol. 2006;13(1):43-54. PMID: 16420392
- Medvedeva EV, Dmitrieva VG, Povarova OV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia. Dokl Biol Sci. 2014;459(1):338-340. PMID: 25532517
- Ziganshina LE, Abakumova T, Vernay L. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2017;4(4):CD007026. PMID: 28390066
- Eremin KO, Kudrin VS, Saranstseva SV, et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493-1500. PMID: 16362768